AI
PBYI icon

Atom Investors’s Puma Biotechnology PBYI Stock Holding History

Atom Investors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-236,911
Closed -$2.55M – 290
2019
Q3 		$2.55M Buy
236,911
+145,626
+160% +$1.57M 0.17% 141
2019
Q2 		$1.16M Buy
91,285
+59,251
+185% +$1.36M 0.08% 242
2019
Q1 		$1.24M Buy
+32,034
New +$978K 0.11% 161

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Atom Investors's PBYI Position: Q4 2019 in Review

Atom Investors sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 236,911 shares — an estimated $2.55M sold.

Atom Investors first reported a position in PBYI in Q1 2019 and held it in 3 quarters. The position peaked at $2.55M in Q3 2019. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

  • Atom Investors reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
  • Atom Investors sold 236,911 Puma Biotechnology shares in Q4 2019, an estimated $2.55M.
  • Atom Investors first reported a position in Puma Biotechnology in Q1 2019 and held it in 3 quarters.
  • Atom Investors's Puma Biotechnology position peaked at $2.55M in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on Atom Investors's 13F filing for Q4 2019, filed 13 Feb 2020.